Get access

Leflunomide therapy for BK virus allograft nephropathy after pediatric kidney transplantation

Authors


Hee G. Kang, MD, PhD, Associate Professor, Department of Pediatrics, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

103 Daehak-ro, Jongno-gu, Seoul 110-799, Korea

Tel.: +82-2-2072-0658

Fax: +82-2-2072-3455

E-mail: kanghg1@gmail.com

Abstract

The BK virus (BKV) can be reactivated with immunosuppressive treatment in renal allograft recipients, which can result in interstitial nephritis (BKV-associated nephropathy, BKVAN) and lead to renal allograft failure. Recently, leflunomide has been reported in some case series of BKVAN with favorable results. Most studies have included only adult patients, we herein report a pediatric case and include a literature review. The patient was a nine-yr-old female with end-stage renal disease due to hypoxic kidney injury. A deceased donor renal transplant was performed and good initial allograft function was achieved following treatment with prednisolone, tacrolimus and mycophenolate mofetil. The serum Cr level increased to 1.6 mg/dL over the following four-month period. A kidney biopsy revealed pathologic findings of acute cellular rejection and BK nephropathy. After methylprednisolone pulse therapy was administered to control acute rejection, the tacrolimus dose was reduced, and intravenous immunoglobulin treatment and leflunomide therapy were administered to control the BKVAN. Over the following 18 months, the viral load steadily decreased and remained below 100 copies/mL in the plasma. Leflunomide therapy in addition to a reduction of the immunosuppressive therapies resulted in a significant decline in the BK viral load without further deterioration of renal function.

Get access to the full text of this article

Ancillary